C4 Therapeutics, Inc. - Common Stock (CCCC) — AI analysis & news
C4 Therapeutics, Inc. - Common Stock (CCCC) stock: 12 recent news items, slightly positive aggregate sentiment, AI analysis and market context on BestAIBroker.
Current sentiment read
Across the last 12 indexed CCCC stories, aggregate finance-aware sentiment is slightly positive (+0.15 on a -1 to +1 scale).
Latest CCCC news
- City Therapeutics allocated no shares to half of IPO orders - report - Investing.com · Investing.com
- City Therapeutics Raises $200 Million in Upsized US IPO · Bloomberg
- Nvidia-Backed AI Biotech Iambic Up 16% After $150 Million IPO · Bloomberg
- JPMorgan initiates C4 Therapeutics stock coverage at Overweight By Investing.com - Investing.com India · Investing.com India
- Defence Therapeutics appoints Sherry Aulin to board - Investing.com India · Investing.com India
- Merck licenses a KRAS G12D inhibitor for $400M upfront - endpoints.news · endpoints.news
- CRISPR Therapeutics stock price target reaffirmed at $80 by Citizens - Investing.com Canada · Investing.com Canada
- CRISPR Therapeutics stock price target reaffirmed at $80 by Citizens - Investing.com India · Investing.com India
- CRISPR Therapeutics stock analysis: pipeline catalysts vs. financial reality - Investing.com · Investing.com
- Cathie Wood’s ARK adds to Scribe Therapeutics stock position By Investing.com - Investing.com South Africa · Investing.com South Africa
- Cathie Wood’s ARK adds to Scribe Therapeutics stock position - Investing.com India · Investing.com India
- Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development · Benzinga
FAQ
What is the current sentiment for CCCC stock?
Aggregate finance-aware sentiment across the last 12 indexed CCCC news stories is slightly positive (+0.15 on a -1 to +1 scale).